Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Observed differences in characteristics of secondary-progressive multiple sclerosis and relapsing-remitting multiple sclerosis patients in the US-based Corrona MS Registry
Multiple Sclerosis
P5 - Poster Session 5 (8:00 AM-9:00 AM)
9-001
To compare characteristics of secondary-progressive (SPMS) vs. relapsing-remitting (RRMS) patients.
The clinical course of patients with different MS subtypes is varied. The Corrona MS Registry in collaboration with National Multiple Sclerosis Society studies real-world burden of disease and safety/effectiveness of MS disease modifying therapies (DMTs).
Corrona MS is a US multicenter, observational registry. Means and proportions of enrollment visit characteristics were compared between SPMS vs. RRMS using pair-wise statistical comparisons. 
As of 1/22/19, 557 RRMS and 80 SPMS patients were enrolled. SPMS vs. RRMS patients were older (57.0, 48.6 years, p<0.0001), less frequently female (68.8%, 76.4%, p=0.1351), had longer disease duration (19.9, 12.1 years, p<0.0001), and more frequently rated as worsening/not improving on current DMT (50.1%, 62.5% and 45.7%, 58.0%). Functional systems impacted in SPMS vs. RRMS were pyramidal (86.2%, 51.5%, p<0.0001); sensory (71.8%, 71.2%), bowel/bladder (62.5%, 39.9%), cerebellar (50.0%, 39.5%) and cerebral (41.2%, 34.5%). Mean doctor-reported relapses in prior 12 months was 0.3. SPMS had higher mean 25-foot-walk (11.4, 6.2 seconds, p=0.0001) and Nine-Hole Peg test times (32.3,  23.7 seconds, p=0.0001) and lower symbol digit modality test score (39.4, 48.9 p=0.0001). For Patient Determined Disease Step (PDDS) categories, 3.8% vs. 40.0% had no disability, 6.2% vs. 22.7%, 5.0% vs. 9.2% and 16.2% vs. 12.4% had mild, moderate and unassisted gait disability, respectively. 68.7% vs. 15.6% had PDDS score equivalent of ≥6.0 on Expanded Disability Status Scale. Mean physical and psychological subscale scores of MS Impact Scale were 44.2 vs. 24.1 (p<0.0001) and 32.4 vs. 28.0 (p=0.1282). 17.5% vs. 62.0% were employed (p< 0.0001). 

 SPMS and RRMS patients in Corrona MS demonstrate important differences in age, disease duration, functional system involvement, disease measures, employment status and patient/clinician DMT response impression. Corrona MS can explore phenotypic differences between subtypes, such as active vs. non-active SPMS. 

Authors/Disclosures
Daniel Kantor, MD, FÂ鶹´«Ã½Ó³»­ (Medical Partnership 4 MS+)
PRESENTER 		Dr. Kantor has received personal compensation for serving as an employee of Gateway Institute for Brain Research. Dr. Kantor has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Kantor has a non-compensated relationship as a HAP with MSFous (MSF) that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Kantor has a non-compensated relationship as a Medical Board with MS Views & News that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Bruce F. Bebo, Jr., PhD (National Multiple Sclerosis Society) No disclosure on file
Patricia K. Coyle, MD, FÂ鶹´«Ã½Ó³»­ (SUNY At Stony Brook) Dr. Coyle has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Accordant. Dr. Coyle has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Coyle has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Sanofi Genzyme. Dr. Coyle has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Coyle has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for GlaxoSmithKline. Dr. Coyle has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Horizon Therapeutics. The institution of Dr. Coyle has received research support from CorEvitas LLC. The institution of Dr. Coyle has received research support from Genentech/Roche. The institution of Dr. Coyle has received research support from NINDS. The institution of Dr. Coyle has received research support from Sanofi Genzyme. The institution of Dr. Coyle has received research support from Cleveland Clinic.
Edward Fox, MD, PhD, FÂ鶹´«Ã½Ó³»­ Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GW Pharmaceuticals. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Bristol Myers Squibb. The institution of Dr. Fox has received research support from Biogen. The institution of Dr. Fox has received research support from Genentech. The institution of Dr. Fox has received research support from Celgene - BMS. The institution of Dr. Fox has received research support from Chugai. The institution of Dr. Fox has received research support from Novartis. The institution of Dr. Fox has received research support from EMD-Serono. The institution of Dr. Fox has received research support from TG Therapeutics. The institution of Dr. Fox has received research support from AbbVie. The institution of Dr. Fox has received research support from Sanofi Genzyme. The institution of Dr. Fox has received research support from AbbVie.
Robert A. Bermel, MD, FÂ鶹´«Ã½Ó³»­ (Cleveland Clinic) Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi/Genzyme. Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/Roche. Dr. Bermel has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Bermel has received research support from Biogen. The institution of Dr. Bermel has received research support from Roche. The institution of Dr. Bermel has received research support from Novartis. Dr. Bermel has received intellectual property interests from a discovery or technology relating to health care.
Jeffrey Greenberg No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Nicholas LaRocca, PhD (National Multiple Sclerosis Society) No disclosure on file
Aaron E. Miller, MD, FÂ鶹´«Ã½Ó³»­ (Mt Sinai School Of Med) Dr. Miller has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Accordant Health Services (Caremark). Dr. Miller has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Corevitas (formerly known as Corrona). Dr. Miller has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for MAPI=Pharma. Dr. Miller has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Viatris (Mylan). Dr. Miller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint Global. Dr. Miller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Miller has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen Idec. Dr. Miller has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion. Dr. Miller has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen (Horizon Therapeutics). Dr. Miller has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Sterne Kessler. Dr. Miller has received publishing royalties from a publication relating to health care.